PT  - JOURNAL ARTICLE
AU  - Williams, Thomas C.
AU  - Lyttle, Mark D
AU  - Cunningham, Steve
AU  - Sinha, Ian
AU  - Swann, Olivia
AU  - Maxwell-Hodkinson, Abigail
AU  - Roland, Damian
AU - on behalf of the Paediatric Emergency Research in the UK and Ireland (PERUKI)
TI  - Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study”
AID  - 10.1101/2021.04.18.21255700
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.18.21255700
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.18.21255700.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.18.21255700.full
AB  - Background Bronchiolitis (most frequently caused by Respiratory Syncytial Virus; RSV) is a common winter disease predominantly affecting children under one year of age. It is a common reason for presentations to an Emergency Department (ED) and frequently results in hospital admission, contributing to paediatric units approaching or exceeding capacity each winter. During the SARS-CoV-2 pandemic, the circulation of RSV was dramatically reduced in the United Kingdom and Ireland. Evidence from the Southern Hemisphere and other European countries suggests that as social distancing restrictions for SARS-CoV-2 are relaxed, RSV infection returns, causing delayed or even summer epidemics, with different age distributions.Study question The ability to track, anticipate and respond to a surge in RSV cases is critical for planning acute care delivery. There is an urgent need to understand the onset of RSV spread at the earliest opportunity. This will influence service planning, to inform clinicians whether the population at risk is a wider age range than normal, and whether there are changes in disease severity. This information is also needed to inform decision on the timing of passive immunisation of children at higher risk of hospitalisation, intensive care admission or death with RSV infection, which is a public health priority.Methods and likely impact This multi-centre prospective observational cohort study will use a well-established research network (Paediatric Emergency Research in the UK and Ireland, PERUKI) to report in real time cases of RSV infection in children aged under two years, through the collection of essential, but non-identifying patient information. Forty centres will gather initial data on age, index of multiple deprivation quintile, clinical features on presentation, and co-morbidities. Each case will be followed up at 7 days to identify treatment, viral diagnosis and outcome. Information be released on a weekly basis and used to support clinical decision making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Williams is the recipient of a Wellcome Trust Award [204802/Z/16/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol will be submitted to the Integrated Research Application System; in view of the urgency needed to take this project forward, and the fact that no patient identifiable information will be collected, we believe it to be exempt from Research Ethics Committee (REC) Review. This is also in keeping with the Control of Patient Information Notice (Covid-19 Notice under Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002) last reviewed 3rd February 2021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs this is a study protocol no data are yet available. Once available, anonymised, non-patient identifiable data will be stored on a RedCap server hosted by University of West of England, Bristol, United Kingdom (See Data input, storage and management).